Gregg Klang is CEO and founder of CERN Corp. The company’s focus is its patented application of low-level light therapy using germicidal light as an alternative to drug- and chemistry-based treatments for fungal and bacterial vaginitis, thus addressing a growing unmet need. Gregg’s academic background includes an undergraduate degree from the University of California as well as an M.B.A. from Pepperdine’s Graziadio Business School. He holds a number of patents in the medical device sector as well as other industries. Gregg has worked in strategic sales and management in a number of companies.